Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Fetal Medicine Research Center, University of Barcelona, Barcelona, Spain.
Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD014876. doi: 10.1002/14651858.CD014876.pub2.
Neonates may undergo surgery because of malformations such as diaphragmatic hernia, gastroschisis, congenital heart disease, and hypertrophic pyloric stenosis, or complications of prematurity, such as necrotizing enterocolitis, spontaneous intestinal perforation, and retinopathy of prematurity that require surgical treatment. Options for treatment of postoperative pain include opioids, non-pharmacological interventions, and other drugs. Morphine, fentanyl, and remifentanil are the opioids most often used in neonates. However, negative impact of opioids on the structure and function of the developing brain has been reported. The assessment of the effects of opioids is of utmost importance, especially for neonates in substantial pain during the postoperative period.
To evaluate the benefits and harms of systemic opioid analgesics in neonates who underwent surgery on all-cause mortality, pain, and significant neurodevelopmental disability compared to no intervention, placebo, non-pharmacological interventions, different types of opioids, or other drugs.
We searched Cochrane CENTRAL, MEDLINE via PubMed and CINAHL in May 2021. We searched the WHO ICTRP, clinicaltrials.gov, and ICTRP trial registries. We searched conference proceedings, and the reference lists of retrieved articles for RCTs and quasi-RCTs. SELECTION CRITERIA: We included randomized controlled trials (RCTs) conducted in preterm and term infants of a postmenstrual age up to 46 weeks and 0 days with postoperative pain where systemic opioids were compared to 1) placebo or no intervention; 2) non-pharmacological interventions; 3) different types of opioids; or 4) other drugs. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were pain assessed with validated methods, all-cause mortality during initial hospitalization, major neurodevelopmental disability, and cognitive and educational outcomes in children more than five years old. We used the fixed-effect model with risk ratio (RR) and risk difference (RD) for dichotomous data and mean difference (MD) for continuous data. We used GRADE to assess the certainty of evidence for each outcome.
We included four RCTs enrolling 331 infants in four countries across different continents. Most studies considered patients undergoing large or medium surgical procedures (including major thoracic or abdominal surgery), who potentially required pain control through opioid administration after surgery. The randomized trials did not consider patients undergoing minor surgery (including inguinal hernia repair) and those individuals exposed to opioids before the beginning of the trial. Two RCTs compared opioids with placebo; one fentanyl with tramadol; and one morphine with paracetamol. No meta-analyses could be performed because the included RCTs reported no more than three outcomes within the prespecified comparisons. Certainty of the evidence was very low for all outcomes due to imprecision of the estimates (downgrade by two levels) and study limitations (downgrade by one level). Comparison 1: opioids versus no treatment or placebo Two trials were included in this comparison, comparing either tramadol or tapentadol with placebo. No data were reported on the following critical outcomes: pain; major neurodevelopmental disability; or cognitive and educational outcomes in children more than five years old. The evidence is very uncertain about the effect of tramadol compared with placebo on all-cause mortality during initial hospitalization (RR 0.32, 95% Confidence Interval (CI) 0.01 to 7.70; RD -0.03, 95% CI -0.10 to 0.05, 71 participants, 1 study; I² = not applicable). No data were reported on: retinopathy of prematurity; or intraventricular hemorrhage. Comparison 2: opioids versus non-pharmacological interventions No trials were included in this comparison. Comparison 3: head-to-head comparisons of different opioids One trial comparing fentanyl with tramadol was included in this comparison. No data were reported on the following critical outcomes: pain; major neurodevelopmental disability; or cognitive and educational outcomes in children more than five years old. The evidence is very uncertain about the effect of fentanyl compared with tramadol on all-cause mortality during initial hospitalization (RR 0.99, 95% CI 0.59 to 1.64; RD 0.00, 95% CI -0.13 to 0.13, 171 participants, 1 study; I² = not applicable). No data were reported on: retinopathy of prematurity; or intraventricular hemorrhage. Comparison 4: opioids versus other analgesics and sedatives One trial comparing morphine with paracetamol was included in this comparison. The evidence is very uncertain about the effect of morphine compared with paracetamol on COMFORT pain scores (MD 0.10, 95% CI -0.85 to 1.05; 71 participants, 1 study; I² = not applicable). No data were reported on the other critical outcomes, i.e. major neurodevelopmental disability; cognitive and educational outcomes in children more than five years old, all-cause mortality during initial hospitalization; retinopathy of prematurity; or intraventricular hemorrhage.
AUTHORS' CONCLUSIONS: Limited evidence is available on opioid administration for postoperative pain in newborn infants compared to either placebo, other opioids, or paracetamol. We are uncertain whether tramadol reduces mortality compared to placebo; none of the studies reported pain scores, major neurodevelopmental disability, cognitive and educational outcomes in children older than five years old, retinopathy of prematurity, or intraventricular hemorrhage. We are uncertain whether fentanyl reduces mortality compared to tramadol; none of the studies reported pain scores, major neurodevelopmental disability, cognitive and educational outcomes in children older than five years old, retinopathy of prematurity, or intraventricular hemorrhage. We are uncertain whether morphine reduces pain compared to paracetamol; none of the studies reported major neurodevelopmental disability, cognitive and educational outcomes in children more than five years old, all-cause mortality during initial hospitalization, retinopathy of prematurity, or intraventricular hemorrhage. We identified no studies comparing opioids versus non-pharmacological interventions.
新生儿可能因膈疝、腹裂、先天性心脏病和肥厚性幽门狭窄等畸形,或因坏死性小肠结肠炎、自发性肠穿孔和早产儿视网膜病变等早产并发症而接受手术治疗,这些疾病都需要手术治疗。术后疼痛的治疗选择包括阿片类药物、非药物干预和其他药物。在新生儿中最常使用的阿片类药物有吗啡、芬太尼和瑞芬太尼。然而,已经有报道称阿片类药物对发育中大脑的结构和功能有负面影响。因此,评估阿片类药物的效果非常重要,尤其是对于术后处于严重疼痛状态的新生儿。
评估与无干预、安慰剂、非药物干预、不同类型的阿片类药物或其他药物相比,全身性阿片类药物镇痛在接受手术的新生儿中的全因死亡率、疼痛和显著神经发育障碍方面的获益和危害。
我们于 2021 年 5 月在 Cochrane 中心对照试验数据库(CENTRAL)、PubMed 上的 MEDLINE 和 CINAHL 中进行了检索。我们还检索了世界卫生组织国际临床试验注册平台(WHO ICTRP)、ClinicalTrials.gov 和 ICTRP 试验注册库。我们检索了会议记录,并对随机对照试验和准随机对照试验的文章参考文献进行了检索。
我们纳入了在妊娠龄(postmenstrual age)达到 46 周及 0 天之前的早产儿和足月儿中进行的术后疼痛的随机对照试验(RCTs),其中全身性阿片类药物与 1)安慰剂或无干预;2)非药物干预;3)不同类型的阿片类药物;或 4)其他药物进行了比较。
我们使用标准的 Cochrane 方法。我们的主要结局是采用经过验证的方法评估的疼痛、初始住院期间的全因死亡率、主要神经发育障碍以及 5 岁以上儿童的认知和教育结局。我们使用固定效应模型,对二分类数据采用风险比(RR)和风险差(RD),对连续数据采用均数差(MD)。我们使用 GRADE 评估每个结局的证据确定性。
我们纳入了四项 RCTs,涉及来自不同大陆的四个国家的 331 名婴儿。大多数研究认为患者接受了大或中手术(包括胸或腹部大手术),术后可能需要通过阿片类药物来控制疼痛。随机试验未考虑接受小手术(包括腹股沟疝修补术)和在试验开始前接受阿片类药物治疗的患者。两项 RCT 比较了阿片类药物与安慰剂;一项比较了芬太尼与曲马多;还有一项比较了吗啡与对乙酰氨基酚。由于估计值的不精确性(降级两级)和研究局限性(降级一级),因此无法进行任何 meta 分析。由于结局的证据确定性非常低(所有结局均因不精确性降级两级,因研究局限性降级一级),所有结局的证据都非常不确定。
比较 1:阿片类药物与无治疗或安慰剂 两项试验比较了曲马多或他喷他多与安慰剂,均未报告以下关键结局的数据:疼痛;主要神经发育障碍;或 5 岁以上儿童的认知和教育结局。与安慰剂相比,曲马多对初始住院期间全因死亡率的影响的证据非常不确定(RR 0.32,95%置信区间(CI)0.01 至 7.70;RD -0.03,95%CI -0.10 至 0.05,71 名参与者,1 项研究;I²:不适用)。未报告早产儿视网膜病变或脑室内出血的数据。
比较 2:阿片类药物与非药物干预 未纳入该比较的试验。
比较 3:不同阿片类药物的头对头比较 一项比较了芬太尼与曲马多的试验被纳入该比较。与安慰剂相比,芬太尼对初始住院期间全因死亡率的影响的证据非常不确定(RR 0.99,95%CI 0.59 至 1.64;RD 0.00,95%CI -0.13 至 0.13,171 名参与者,1 项研究;I²:不适用)。未报告早产儿视网膜病变或脑室内出血的数据。
比较 4:阿片类药物与其他镇痛剂和镇静剂 一项比较了吗啡与对乙酰氨基酚的试验被纳入该比较。与对乙酰氨基酚相比,吗啡对 COMFORT 疼痛评分的影响的证据非常不确定(MD 0.10,95%CI -0.85 至 1.05;71 名参与者,1 项研究;I²:不适用)。未报告其他关键结局,即主要神经发育障碍;5 岁以上儿童的认知和教育结局;初始住院期间的全因死亡率;早产儿视网膜病变;或脑室内出血。
与安慰剂、其他阿片类药物或对乙酰氨基酚相比,我们对新生儿术后疼痛中使用阿片类药物的证据有限。我们不确定曲马多是否能降低死亡率;没有研究报告疼痛评分、主要神经发育障碍、5 岁以上儿童的认知和教育结局、早产儿视网膜病变或脑室内出血。我们不确定芬太尼是否能降低死亡率;没有研究报告疼痛评分、主要神经发育障碍、5 岁以上儿童的认知和教育结局、早产儿视网膜病变或脑室内出血。我们不确定吗啡是否能降低疼痛;没有研究报告主要神经发育障碍、5 岁以上儿童的认知和教育结局、初始住院期间的全因死亡率、早产儿视网膜病变或脑室内出血。我们没有发现比较阿片类药物与非药物干预的研究。